Press release
REGENXBIO Inc. (NASDAQ: RGNX) Investor Alert: Lawsuit seeks to recover Losses for Investors
A lawsuit was filed on behalf of investors in REGENXBIO Inc. (NASDAQ: RGNX) shares over alleged securities laws violations.
Investors who purchased shares of REGENXBIO Inc. (NASDAQ: RGNX) have certain options and for certain investors are short and strict deadlines running. Deadline: April 14, 2026 February 9, 2022 and January 27, 2026,. NASDAQ: RGNX investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Rockville, MD based REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. On January 28, 2026, REGENXBIO Inc announced that the FDA placed a clinical hold on its investigational gene therapy RGX-111. REGENXBIO Inc announced that an intraventricular CNS tumor was found in a participant treated in its RGX-111 Phase I/II study.
Shares of REGENXBIO Inc. (NASDAQ: RGNX) declined from $35.73 per share on August 05, 2022, to as low as $7.61 per share on February 19, 2026.
According to the complaint the plaintiff alleges on behalf of purchasers of REGENXBIO Inc. (NASDAQ: RGNX) common shares between February 9, 2022 and January 27, 2026, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between February 9, 2022 and January 27, 2026, the defendants provided investors with material information concerning REGENXBIO's plan to develop and commercialize its product candidate RGX-111, a one-time gene therapy for the treatment of severe Mucopolysaccharidosis Type I, also known as Hurler syndrome, that the Defendants' statements included, among other things, REGENXBIO's positive assertions of RGX-111's future trial success based on continuing positive biomarker and safety data from the ongoing PhaseI/II study, and that the Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning the efficacy and safety of its RGX-111 trial study.
Those who purchased shares of REGENXBIO Inc. (NASDAQ: RGNX) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release REGENXBIO Inc. (NASDAQ: RGNX) Investor Alert: Lawsuit seeks to recover Losses for Investors here
News-ID: 4419412 • Views: …
More Releases from Shareholders Foundation, Inc.
Investigation announced for Long-Term Investors in shares of DexCom, Inc. (NASDA …
An investigation was announced for long-term investors in shares of DexCom, Inc. (NASDAQ: DXCM) concerning potential breaches of fiduciary duties by certain directors and officers of DexCom, Inc.
Investors who are current long term investors in DexCom, Inc. (NASDAQ: DXCM) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ:…
Lawsuit ALERT: Investors who lost money with shares of Kyndryl Holdings, Inc. (N …
An investor, who purchased shares of Kyndryl Holdings, Inc. (NYSE: KD), filed a lawsuit over alleged violations of Federal Securities Laws by Kyndryl Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Kyndryl Holdings, Inc. (NYSE: KD) have certain options and for certain investors are short and strict deadlines running. Deadline: April 13, 2026. NYSE: KD investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
Lawsuit filed for Investors who lost money with shares of Picard Medical, Inc. ( …
An investor, who purchased shares of Picard Medical, Inc. (NYSE: PMI), filed a lawsuit over alleged violations of Federal Securities Laws by Picard Medical, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Picard Medical, Inc. (NYSE: PMI) have certain options and for certain investors are short and strict deadlines running. Deadline: April 13, 2026. NYSE: PMI investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
CoreWeave, Inc. (NASDAQ: CRWV) Investor Alert: Deadline in Lawsuit on March 13, …
A deadline is coming up on March 13, 2026 in the lawsuit filed for certain investors of CoreWeave, Inc. (NASDAQ: CRWV) over alleged securities laws violations by CoreWeave, Inc.
Investors who purchased shares of CoreWeave, Inc. (NASDAQ: CRWV) have certain options and there are strict and short deadlines running. Deadline: March 13, 2026. NASDAQ: CRWV stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the…
More Releases for REGENXBIO
Hunter Syndrome Treatment Market Expands with Enzyme Replacement Innovations | S …
Hunter Syndrome Treatment Market Overview
Hunter Syndrome Treatment Market is forecast to grow from USD 1.2 billion in 2025 to USD 2.0 billion by 2032, growing at a CAGR of 7.4%.
The latest report (2025-2032) on the Hunter Syndrome Treatment Market by Coherent Market Insights offers an in-depth analysis of market trends, growth factors, challenges, and competition. It explores market size, revenue, production, consumption, and CAGR, using reliable research methods for accuracy.…
Duchenne Muscular Dystrophy Drugs Market SWOT Analysis by Leading Expert: Pfizer …
Duchenne Muscular Dystrophy Drugs Market is estimated to increase at a growth rate of 10.8% CAGR over the forecast period from 2024 to 2030.
The latest study released on the Global Duchenne Muscular Dystrophy Drugs Market by USD Analytics Market evaluates market size, trend, and forecast to 2034. The Duchenne Muscular Dystrophy Drugs market study covers significant research data and proofs to be a handy resource document for managers, analysts, industry…
Neuronal Ceroid-Lipofuscinoses Market 2032 |Pfizer, Spark Therapeutics, REGENXBI …
DelveInsight's "Neuronal Ceroid-Lipofuscinoses Disease Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Neuronal Ceroid-Lipofuscinoses Disease, historical and forecasted epidemiology as well as the Neuronal Ceroid-Lipofuscinoses Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Neuronal Ceroid-Lipofuscinoses Disease market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted…
Neuronal Ceroid-Lipofuscinoses Market 2032 |Pfizer, Spark Therapeutics, REGENXBI …
DelveInsight's "Neuronal Ceroid-Lipofuscinoses Disease Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Neuronal Ceroid-Lipofuscinoses Disease, historical and forecasted epidemiology as well as the Neuronal Ceroid-Lipofuscinoses Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Neuronal Ceroid-Lipofuscinoses Disease market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted…
Batten Disease Market is Booming Worldwide | Abeona Therapeutics, Regenxbio, Ami …
HTF Market Intelligence published a new research document of 150+pages on "Batten Disease Market Insights, to 2028" with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Batten Disease market was mainly driven by the increasing R&D spending by leading and emerging player, however latest scenario and economic slowdown have…
Mucopolysaccharidosis Therapeutics Market May Set Huge Growth by 2027 | Denali T …
The Mucopolysaccharidosis Therapeutics Market Report addresses a 360-degree outline of significant market players that will affect the general development of industry. It offers itemized and brief examination of different key angles like drivers, limitations and worldwide freedoms. This market report dissects gigantic information identified with market size, share, creating patterns and cutthroat situations regarding all areas like North America, Europe, China and Japan and so forth the report offers request…
